Opportunity

A commercialization path centered on SAF feedstocks as the first wedge.

C1 Foundry is not trying to become a full fuel company on day one. The near-term focus is narrower: intermediates and lipid pathways relevant to SAF supply chains, where existing demand and downstream infrastructure create a more disciplined entry point.

Why SAF first

SAF feedstocks are the first market because demand is urgent and the downstream pathway already exists.

Aviation decarbonization pressure is real, and SAF demand is shaped by regulation, procurement pressure, and the need for lower-carbon drop-in fuel pathways. That does not make the biology easy, but it does mean there is a defined market pull for scalable feedstocks that can enter existing refining systems.

The point is not that the whole SAF problem is solved. It is that feedstocks can be a clearer wedge than trying to own every step from carbon input to finished fuel.

Why feedstocks

Feedstocks are a more realistic starting point than becoming a refinery company.

C1 Foundry does not need to solve the entire fuel value chain to have a useful commercial role. A more credible starting position is to produce intermediates and lipid feedstocks that can plug into downstream upgrading and refining infrastructure already being built around SAF.

That keeps the first business question focused on the biological and process route, not on owning a full refinery stack before the core platform is ready.

Infrastructure fit

Existing SAF infrastructure makes the wedge more coherent than a generic fuels story.

The SAF ecosystem already includes refiners, project developers, airlines, policy incentives, and offtake pressure. That does not remove techno-economic risk, but it creates a clearer path for a feedstock company than a market where all downstream integration would need to be invented from scratch.

Techno-economics

The business case still depends on productivity, scalability, and integration with existing energy systems.

A SAF feedstock route only matters if feedstock supply, conversion performance, energy demand, recovery, and logistics can support a believable cost structure. Scale, capital intensity, hydrogen availability, and downstream processing all remain live constraints. None of that can be hidden behind market enthusiasm.

In other words, SAF is a commercialization wedge, not a shortcut. The route still has to earn its place on process economics and industrial integration.

Platform scope

The broader C1 platform still matters, but it should follow a disciplined first market.

The longer-term platform can still support acetate intermediates, terpenoids, specialty molecules, and other carbon utilization pathways. The commercialization logic is simply that SAF feedstocks provide the sharpest first question: can the platform produce molecules the market needs, in a form that existing infrastructure can use, under constraints that make economic sense?